ClinicalTrials.gg
RecruitingNCT05165927Updated Dec 11, 2024

Comparison of Methods in Post Operative Hip Arthroscopy Rehabilitation

An interventional study of BFR in Hip Injuries, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Hip Injuries with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Hip Injuries · United States.

Planned enrollment
3rd of 15
120 · median 68
Started
2022
with 3 others
No phase
12 of 26
2 open now
Registered
19th of 26
by date

Among the 26 studies in Hip Injuries with a site in United States, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2022, is one of 12 with no phase, and was the 19th registered.

Hip Injuries

66 studies on the registry are indexed under Hip Injuries; 12 are open to participants now.

Browse Hip Injuries studies →

Open to participants now

7 of the 26 studies in Hip Injuries with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Hip Injuries studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hip Injuries with a site in United States, or all of them as a file.
02

Study summary

The investigators plan to investigate the efficacy of blood flow restriction (BFR) therapy in post operative rehabilitation following hip arthroscopy. BFR has shown to be great at helping the recovery process. SAGA is a well-known smart training technology company, and the investigators aim to partner with SAGA to use the BFR cuffs as the intervention method. The BFR cuff will be added to the current SOC for hip scope PT for the intervention group.

Read the detailed description

Study Design and Research Methods i. Timeline: Treatment Protocol duration 12 weeks per participant beginning post operative day 1 following hip arthroscopy. PRO's will be collected out to 2 years post-surgery and standard rehabilitation will follow the 12-week intervention period for both the control and experimental group. Study will be a 2-year timeline in total.

ii. Procedures: Patients will be randomized to control group, who will undergo Steadman Hawkins Clinic Denver's standard hip arthroscopy rehab protocol (see appendix) or to the intervention group, who will undergo standard rehab protocol with addition of BFR. Subjects will be randomized 1:1 for intervention vs. control and controlled for gender assigned at birth.

iii. Frequency of BFR Training: 6 days per week phase 1, 3 days per week phases 2 and 3 iv. Frequency of clinic visits PT: 1 day per week v. Intervention Group: The following exercises outlined are the specific exercises that will be performed in addition to SOC. Only these exercises will involve the use of the BFR cuff.

  1. Phase 1 (post operative weeks 1-3)

    1. Dosage: 80% limb occlusion pressure (LOP). 30x15x15x15 repetitions with 30 sec rests between sets. At least 1 min rest between exercises with occlusion OFF.
    2. Frequency: All 3 exercises performed at least 6 days per week. The first of these sessions will be performed in clinic supervised by PT to assess LOP and form prior to performance at home
    3. Exercises:

    i. Week 1: quadriceps set, gluteal set, hamstring set ii. Week 2: short arc quad, hook lying adduction/internal rotation isometric, hook lying abduction/external rotation isometric iii. Week 3: long arc quad, bridge, standing hamstring curl

  2. Phase 2 (weeks 4-6)

    1. Dosage: 80% LOP. 30x15x15x15 repetitions with 30 sec rests between sets. At least 1 min rest between exercises with occlusion OFF
    2. Frequency: All 3 resistive exercises performed at least 3 days per week. The first of these sessions will be performed in clinic supervised by PT to assess LOP and form prior to performance at home
    3. Exercises:

    i. Week 4: mini squat, prone hip extension over plinth, quadruped rock ii. Week 5: mid-range squat, modified single leg bridge foot on ball, heel slide strap assist iii. Week 6: step up, standing hip abduction, single leg bridge

  3. Phase 3 (weeks 6-12)

    a. Dosage: 80% LOP at 20-30% 1 RM.1 RM re-evaluated every 2 weeks to adjust resistance prescription. 30x15x15x15 repetitions with 30 sec rests between sets. At least 1 min rest between exercises with occlusion OFF b. Frequency: All 3 resistive exercises performed at least 3 days per week. The first of these sessions will be performed in clinic supervised by PT to assess LOP and form prior to performance at home c. Exercises: i. Weeks 6-12: Single leg squat to 45 deg knee flexion (holding weight as tolerated), single leg Romanian dead lift (holding weight a weight as tolerated), Bulgarian split squat (holding a weight as tolerated)

  4. Phase 4 (12+ weeks) a. BFR intervention will be discontinued at 12 weeks and participants will progress per standard protocol for the remainder of their rehabilitation course vi. Control Group
  1. Control group will follow the standard of care outlined in Appendix A. vii. Criteria for progression within the BFR specific exercise protocol
  1. Regardless of functional performance, patients will not be allowed to progress ahead of the time-based exercise prescription in the BFR protocol. However, if the treating therapist determines that the current week's exercise prescription is too difficult for the patient, subject may return to the prior week's exercise set until able to advance.
03

Conditions studied

  • Hip Injuries

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with labral tears, femoroacetabular impingement syndrome, loose bodies, ligamentum teres tears, and related intra-articular pathology to be treated with hip arthroscopy. Patients must also have access to a smartphone device in order to utilize the SAGA BFR application for use. The application is free to use.

Exclusion criteria

Exclusion Criteria:

  • bilateral hip surgeries to be performed within 12 weeks of each other, concomitant Peri-acetabular osteotomy, soft tissue repairs (hamstring, glute repairs), clinically diagnosed hip dysplasia, and the following BFR :

    • Deep Vein Thrombosis (DVT)
    • Pulmonary Embolism
    • Hemorrhagic/Thrombolytic Stroke
    • Clotting Disorders
    • Hemophilia or taking blood thinners
    • Pregnant or up to 6 months post-partum
    • Untreated Hypertension
    • Untreated Hypotension
    • Rhabdomyolysis or recent traumatic injury
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    BFR Group

    BFR cuffs will be used for specific exercises and added to the current SOC for post hip scope PT.

    Device: BFR

  • No intervention
    SOC Group

    Current SOC for post hip scope PT will be assigned.

Interventions

  • DeviceBFR

    BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.

06

What researchers measure

Primary outcomes

  1. Hip extensor strength

    1. Strength of hip extensors via handheld dynamometry (HHD) and reported as a measure of limb symmetry index (LSI) comparing operative limb to non-operative limb. By 3 months post operatively, patients should be approaching 70% LSI in order to safely initiate impact activities such as jogging. Prior to discharge from therapy, patients should achieve at least 90% LSI per standard protocol.

    Time frame: 2 Years

Secondary outcomes

  1. additional hip musculature strength

    1. Strength of hip flexors, abductors and adductors via handheld dynamometry (HHD) and reported as a measure of limb symmetry index (LSI) comparing operative limb to non-operative limb. By 3 months post operatively, patients should be approaching 70% LSI in order to safely initiate impact activities such as jogging. Prior to discharge from therapy, patients should achieve at least 90% LSI per standard protocol.

    Time frame: 2 Years

  2. single leg squat test

    2. Performance on a Repeated Single Leg Squat test to 45 deg knee flexion over the course of 90 seconds reported as a measure of LSI. Prior to initiation of impact activities such as jogging (usually around 3 months), patient should be approaching 70% LSI per standard protocol and 90% by time of discharge.

    Time frame: 2 Years

  3. i-HOT

    Range 0 (poor health) - 100 (good health); MCD = Δ13

    Time frame: 2 Years

  4. LEFS

    Range 0 (extreme difficulty) - 100 (extreme difficulty); MDIC = Δ 123

    Time frame: 2 Years

  5. PROMIS pain

    PROMIS Pain: Range 0 (low pain) - 100 (high pain); MDC = Δ 85.

    Time frame: 2 Years

  6. Brief Resiliency Score

    Range 1 (low resilience) - 5 (high resilience)

    Time frame: 2 Years

  7. PROMIS physical function

    PROMIS Physical Function: Range 0 (low function) - 100 (high function); MDC = Δ 85

    Time frame: 2 Years

  8. range of motion (ROM)

    MDC = Δ low (1-2.99) to normal (3-4.3) to high (4.31-5)

    Time frame: 2 Years

  9. Tegner Activity Scale

    Range 0 (disability because of knee problems) - 10 (national or international level soccer)

    Time frame: 2 Years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2025, 44 months after the start.

Of 26 non-industry interventional studies with no phase under Hip Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 65. This study's planned 44 months is above that.

Counting every sponsor, half of 28 studies reached it within 26 months; a quarter within 8 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Dec 21, 2021
StartActual
Apr 29, 2022
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05165927
Responsible party
Sponsor
First posted
Dec 21, 2021
Start date
Apr 29, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 11, 2024

Study contacts

Lauren M Heylmun, BS
Contact
lauren.heylmun@cuanschutz.edu
7205169823
James Genuario, MD
principal investigator · University of Colorado SOM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion